| Drug General Information |
| Drug ID |
D07ICV
|
| Former ID |
DNC006909
|
| Drug Name |
GNF-PF-3878
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C25H26N4
|
| Canonical SMILES |
CCN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
|
| InChI |
1S/C25H26N4/c1-2-28-15-17-29(18-16-28)20-13-11-19(12-14-20)26-25-21-7-3-5-9-23(21)27-24-10-6-4-8-22(24)25/h3-14H,2,15-18H2,1H3,(H,26,27)
|
| InChIKey |
CUVBGWMAORETGV-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
GPCR downstream signaling
|
| References |
| REF 1 | J Med Chem. 2006 Oct 19;49(21):6351-63.Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. |
|---|
